Orforglipron was granted one of these The FDA has stated that the initiative is intended to pioneer new ways of bringing these cures and meaningful treatments to the market faster, particularly in areas of high public health need
GLP-1 drugs such as semaglutide are reshaping treatment of obesity, diabetes and cardiovascular disease with broader physiological effects now emerging
Like other GLP-1 medications, dosing is gradually increased to help the body adjust and reduce side effects
Of the few Marketplace plans that cover GLP-1 drugs approved for obesity, all require prior authorization
Ro's strength lies in rapid access for patients who have already researched GLP-1 therapy and want quick initiation
Back Turton, MD, O'Shea, D, Gunn, et al (4 Jan 1996) 'A role for glucagon-like peptide-1 in the central regulation of feeding', Nature , 379, 69-72